BanderasNews
Puerto Vallarta Weather Report
Welcome to Puerto Vallarta's liveliest website!
Contact UsSearch
Why Vallarta?Vallarta WeddingsRestaurantsWeatherPhoto GalleriesToday's EventsMaps
 NEWS/HOME
 EDITORIALS
 ENTERTAINMENT
 VALLARTA LIVING
 TRAVEL / OUTDOORS
 HEALTH / BEAUTY
 HEALTH FOR WOMEN
 HEALTH FOR MEN
 DENTAL HEALTH
 ON ADDICTION
 RESOURCES
 SPORTS
 DAZED & CONFUSED
 PHOTOGRAPHY
 CLASSIFIEDS
 READERS CORNER
 BANDERAS NEWS TEAM
Sign up NOW!

Free Newsletter!
Puerto Vallarta News NetworkHealth & Beauty | March 2005 

Panel Cites 'Information Gap' On Relieving Menopause
email this pageprint this pageemail usRita Rubin - USA TODAY


Risks vs. benefit has been a concern for menopausal symptom drugs. (Photo: Stephen Chernin / Getty Images)
After listening to 1½ days' worth of presentations about treatments for hot flashes and other menopausal symptoms, an independent panel of scientists concluded Wednesday that there is insufficient evidence to wholeheartedly endorse any of them.

"We clearly have an enormous information gap for understanding the best treatments for women who are symptomatic," said Carol Mangione, who chaired a 12-member "state-of-the-science" panel convened by the National Institutes of Health.

The NIH-sponsored Women's Health Initiative, which compared postmenopausal hormones with placebo pills in more than 27,000 women, was designed primarily to see whether long-term therapy could protect women against cardiovascular disease. But women with moderate to severe menopause symptoms were discouraged from participating.

Though WHI researchers reported in July 2002 that the risks of estrogen plus progestin, sold as Prempro, did not outweigh its benefits in study participants, the findings provided relatively few answers for women dealing with menopausal symptoms.

"In the post-Women's Health Initiative era, there has been a lot of confusion about how to manage the symptoms of menopause," said Mangione, a professor of medicine at the University of California, Los Angeles.

Mangione's panel called for a new study to fill the knowledge gaps about treating menopausal symptoms, which it identified as hot flashes, night sweats, vaginal dryness and a possibility of sleep disturbances.

The study should compare the long-term risks and benefits of three to five years of treatment with low-dose hormone therapy, the panel said. Participants should represent a variety of ethnic groups and body sizes to determine the role of such factors in menopausal symptoms and treatment.

"These are very expensive studies to undertake," Mangione acknowledged. "At the same time, this is a condition that affects a lot of women in the United States."

Cynthia Pearson, executive director of the National Women's Health Network, praised the panel's push for more research. "Women can make very good decisions about their own health if they have very good information on which to base those decisions," Pearson said.

The full text of the panel's draft statement is available online at consensus.nih.gov. The final version of the statement will be available at the same Web address in about four weeks.



In accordance with Title 17 U.S.C. Section 107, this material is distributed without profit to those who have expressed a prior interest in receiving
the included information for research and educational purposes • m3 © 2008 BanderasNews ® all rights reserved • carpe aestus